• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine: An Overview of a Promising Compound (CAS No. 1275402-02-2)

4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine (CAS No. 1275402-02-2) is a novel compound that has garnered significant attention in the field of medicinal chemistry and drug discovery. This compound, characterized by its unique adamantane and pyrimidine moieties, has shown promising potential in various therapeutic applications, particularly in the treatment of neurological disorders and cancer. This article provides a comprehensive overview of the chemical structure, synthesis, biological activity, and recent research developments surrounding this compound.

The chemical structure of 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine is defined by its adamantane group, which is a tricyclic cycloalkane with a highly stable and rigid structure. The adamantane moiety is known for its ability to enhance the lipophilicity and bioavailability of compounds, making it an attractive scaffold in drug design. The pyrimidine ring, on the other hand, is a versatile heterocyclic system that is commonly found in many biologically active molecules, including nucleosides and antiviral agents. The presence of the methyl group at the 6-position further modulates the electronic properties and biological activity of the compound.

The synthesis of 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine has been extensively studied, with several efficient routes reported in the literature. One common approach involves the reaction of 1-adamantylamine with 2-chloro-6-methylpyrimidine in the presence of a base such as potassium carbonate. This method yields high purity and good yields, making it suitable for large-scale production. Another notable synthetic route involves the coupling of 1-adamantylamine with 2-amino-6-methylpyrimidine using a copper catalyst, which provides an alternative pathway for accessing this compound.

In terms of biological activity, 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine has demonstrated significant potential as a modulator of various biological targets. Recent studies have shown that this compound exhibits potent neuroprotective effects, making it a promising candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The mechanism of action is believed to involve the modulation of neurotransmitter systems and the reduction of oxidative stress in neuronal cells.

Beyond its neuroprotective properties, 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine has also shown promise in cancer research. Preclinical studies have demonstrated that this compound can inhibit the growth of various cancer cell lines, including those derived from breast, lung, and colon cancers. The anticancer activity is thought to be mediated through multiple mechanisms, including the induction of apoptosis and the inhibition of angiogenesis.

The pharmacokinetic properties of 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine have been evaluated in several animal models. These studies have revealed that the compound exhibits favorable pharmacokinetic profiles, with good oral bioavailability and a long half-life. These characteristics are crucial for ensuring effective drug delivery and sustained therapeutic effects.

To further validate its therapeutic potential, clinical trials are currently underway to assess the safety and efficacy of 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine in human subjects. Early results from phase I trials have shown that the compound is well-tolerated at various dose levels, with no significant adverse effects reported. These findings are encouraging and pave the way for more advanced clinical studies.

In addition to its therapeutic applications, 4-(Adamantan-1-yl)-6-methylpyrimidin-2-amine has also been explored for its potential as a research tool in biochemical and cellular assays. Its unique structural features make it an ideal candidate for probing specific biological pathways and interactions. For instance, it has been used to study the role of specific receptors in signal transduction processes and to investigate the mechanisms underlying neurodegeneration.

The future prospects for 4-(Adamantan-1-y l)-6-methylpyrimidin - 2 - amine are promising. Ongoing research continues to uncover new insights into its biological activities and potential therapeutic applications. As more data becomes available from clinical trials and preclinical studies, it is likely that this compound will play an increasingly important role in the development of novel treatments for various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)